Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Indian J Nephrol ; 32(5): 423-429, 2022.
Article in English | MEDLINE | ID: mdl-36568588

ABSTRACT

Introduction: Deceased donor renal transplantation (DDRT) poses special immunological challenges; particularly in resource-poor scenarios. There is substantial evidence that rabbit antithymocyte globulin (rATG) is superior to interleukin-2 receptor blocker and placebo among patients at high immunological risk. However, due to the lack of randomized controlled trials, this remains controversial in DDRT maintained on tacrolimus/mycophenolic acid/steroids. Here, in this study, we compared the clinical outcomes of induction with rATG therapy to no-induction therapy. Methods: The study was a single-center, retrospective cohort study. A total of 62 patients were divided into two groups, based on induction immunosuppression; induction with rATG (N = 25) and no-induction group (N = 37). Both groups received tacrolimus/mycophenolate mofetil sodium/prednisolone as maintenance immunosuppression. The main outcomes were incidence of acute rejection (AR) within the first year and graft survival at the end of 1 year. Results: The AR at the end of 1-year was reported as 8% and 27% for the induction and no-induction groups (P = 0.07), respectively. A total of 15 patients died. Patient survival rates at 12 months were 83.8% (no-induction) and 64.0% (induction; P = 0.094). Death-censored graft survival rates, 12 months after transplantation, were similar in both treatment groups (83.7% vs. 83.5%, P = 0.972). The incidence of death with functioning graft was significantly high in the induction group (28% vs. 5.4%, P = 0.045). Conclusion: The incidence of AR was less in patients who received rATG induction compared with patients who did not receive any form of induction. An added advantage of induction with ATG in terms of reduced incidence of AR must be weighed against high incidence of infection, death with functioning graft, and death.

2.
Indian J Nephrol ; 32(3): 262-265, 2022.
Article in English | MEDLINE | ID: mdl-35814327

ABSTRACT

Introduction: The impact of Ramadan fasting in patients with chronic kidney disease (CKD) remains less studied and with inconsistent results. In this study, we tried to look at the impact of Ramadan fasting on renal function in patients with CKD. Materials and Methods: In this prospective observational study, we included 28 adult CKD patients. All relevant biochemical parameters including renal function tests were done in the month before Ramadan fasting and within 3 months after Ramadan. Urine output, body weight, and blood pressure were also monitored during Ramadan and after the end of Ramadan for at least 10 days. Results: All the 28 patients (mean age: 46 ± 12 years) included in the study managed to fast for the whole month, and none displayed any new clinical symptoms or signs. The renal function worsened in four (14.28%), and it was significant in those with CKD Stages 4 and 5 (P < 0.003). Conclusion: Stable CKD patients can fast with careful monitoring; however, there is a risk of renal function deterioration in advanced CKD.

3.
Indian J Nephrol ; 32(2): 156-159, 2022.
Article in English | MEDLINE | ID: mdl-35603102

ABSTRACT

Glomerular diseases are one of the most challenging entities in terms of diagnosis and management, especially when associated with systemic illnesses such as malignant disorders. Herein, a case of crescentic glomerulonephritis (CrGN) associated with polycythaemia vera (PV) in a 50-year-old female is described. She presented with bilateral pedal oedema, splenomegaly, renal dysfunction and severe proteinuria. On evaluation, we found PV and CrGN. Renal involvement in PV is rare and generally considered as a manifestation of hypervolemia or high-viscosity-induced renal hyper-perfusion and hyper-filtration. This is a unique case of immunologically-mediated renal disease in PV.

4.
Indian J Nephrol ; 29(6): 424-426, 2019.
Article in English | MEDLINE | ID: mdl-31798226

ABSTRACT

Crystal-induced acute kidney injury (AKI) is caused by the intratubular precipitation of crystals, which results in obstruction and kidney injury. Levofloxacin is commonly used fluoroquinolone antibiotic especially for respiratory and urinary tract infections. It rarely causes any serious adverse events. Several cases of crystal nephropathy after ciprofloxacin use have been reported. Pre-existing renal dysfunction, high dose of the drug, and advanced age are considered as risk factors. To best of our knowledge, only two cases of crystal nephropathy due to levofloxacin use have been reported, we add a new one to it. The patient responded to conservative treatment with complete recovery on follow-up.

SELECTION OF CITATIONS
SEARCH DETAIL